vs

Side-by-side financial comparison of ASTRAZENECA PLC (AZN) and ROYAL BANK OF CANADA (RY). Click either name above to swap in a different company.

ASTRAZENECA PLC is the larger business by last-quarter revenue ($14.5B vs $13.1B, roughly 1.1× ROYAL BANK OF CANADA). ROYAL BANK OF CANADA runs the higher net margin — 32.2% vs 16.9%, a 15.3% gap on every dollar of revenue.

AstraZeneca plc (AZ) is a Swedish-British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

The Royal Bank of Canada is a Canadian multinational financial services company and the largest bank in Canada by market capitalization. The bank serves over 18 million clients and has more than 98,000 employees worldwide. Founded in 1864 in Halifax, Nova Scotia, it maintains its corporate headquarters in Toronto and its head office in Montreal. RBC's institution number is 003. In November 2017, RBC was added to the Financial Stability Board's list of global systemically important banks.

AZN vs RY — Head-to-Head

Bigger by revenue
AZN
AZN
1.1× larger
AZN
$14.5B
$13.1B
RY
Higher net margin
RY
RY
15.3% more per $
RY
32.2%
16.9%
AZN

Income Statement — Q2 FY2025 vs Q1 FY2026

Metric
AZN
AZN
RY
RY
Revenue
$14.5B
$13.1B
Net Profit
$2.4B
$4.2B
Gross Margin
82.9%
Operating Margin
24.3%
Net Margin
16.9%
32.2%
Revenue YoY
11.7%
Net Profit YoY
27.0%
EPS (diluted)
$1.57

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AZN
AZN
RY
RY
Q1 26
$13.1B
Q3 25
$12.4B
Q2 25
$14.5B
$11.4B
Q2 24
$12.9B
Q2 23
$11.4B
Q2 22
$10.8B
Net Profit
AZN
AZN
RY
RY
Q1 26
$4.2B
Q3 25
$4.0B
Q2 25
$2.4B
$3.2B
Q2 24
$1.9B
Q2 23
$1.8B
Q2 22
$360.0M
Gross Margin
AZN
AZN
RY
RY
Q1 26
Q3 25
Q2 25
82.9%
Q2 24
83.1%
Q2 23
82.8%
Q2 22
72.2%
Operating Margin
AZN
AZN
RY
RY
Q1 26
Q3 25
Q2 25
24.3%
Q2 24
21.2%
Q2 23
21.5%
Q2 22
5.0%
Net Margin
AZN
AZN
RY
RY
Q1 26
32.2%
Q3 25
31.9%
Q2 25
16.9%
28.0%
Q2 24
14.9%
Q2 23
15.9%
Q2 22
3.3%
EPS (diluted)
AZN
AZN
RY
RY
Q1 26
Q3 25
Q2 25
$1.57
Q2 24
$1.24
Q2 23
$1.17
Q2 22
$0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AZN
AZN
RY
RY
Cash + ST InvestmentsLiquidity on hand
$7.1B
$33.7B
Total DebtLower is stronger
Stockholders' EquityBook value
$44.8B
$102.1B
Total Assets
$112.4B
$1709.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AZN
AZN
RY
RY
Q1 26
$33.7B
Q3 25
$25.5B
Q2 25
$7.1B
$35.5B
Q2 24
$6.9B
Q2 23
$5.7B
Q2 22
$4.8B
Stockholders' Equity
AZN
AZN
RY
RY
Q1 26
$102.1B
Q3 25
$99.0B
Q2 25
$44.8B
$96.7B
Q2 24
$39.6B
Q2 23
$37.4B
Q2 22
$36.0B
Total Assets
AZN
AZN
RY
RY
Q1 26
$1709.9B
Q3 25
$1626.4B
Q2 25
$112.4B
$1636.8B
Q2 24
$104.3B
Q2 23
$96.5B
Q2 22
$96.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AZN
AZN
RY
RY
Operating Cash FlowLast quarter
$27.7B
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
6.55×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AZN
AZN
RY
RY
Q1 26
$27.7B
Q3 25
$21.2B
Q2 25
$7.2B
Q2 24
Q2 23
Q2 22
Cash Conversion
AZN
AZN
RY
RY
Q1 26
6.55×
Q3 25
5.36×
Q2 25
2.24×
Q2 24
Q2 23
Q2 22

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons